viewIncanthera plc

Incanthera completes £350,000 fundraising, with ImmuPharma increasing stake

“ImmuPharma is a strong supporter of Incanthera,” said chief executive Dimitri Dimitriou

ImmuPharma PLC -

ImmuPharma PLC (LON:IMM) has increased its stake in Incanthera PLC (AQSE:INC) as the developer of an innovative sun cream raised £350,000 in a share subscription.

As part of an agreement entered into at the time of Incanthera’s flotation on the AQSE Growth Market in February, ImmuPharma has increased its stake to 15.35% as it subscribed for £250,000 of shares at the float price of 9.5p apiece.

Tim McCarthy, chairman of both companies, and several other directors and other employees of Incanthera subscribed for the remaining £100,000 at the same price.

McCarthy now has a 6.01% stake, while chief executive Simon Ward upped his stake to 4.11%.

Ward said: “Incanthera welcomes the completion of the subscription agreement by ImmuPharma and acknowledges their continued support and belief of the potential within our company and our pipeline.

“Similarly, I welcome the commitment of my fellow directors and management for their decisions to subscribe alongside our chairman, for additional shares, which underlines their dedication to the future success of the company for the benefit of both patients and shareholders.”

Dimitri Dimitriou, ImmuPharma's chief executive officer, added: “ImmuPharma is a strong supporter of Incanthera, sharing common goals of progressing both of our therapeutic pipelines to benefit the long term health of patients, globally.

“We are extremely pleased to note Incanthera's two recent announcements, evidencing great progress towards its immediate goal of taking its lead product Sol to market.”

Incanthera’s lead product is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers, which has achieved proof of concept and is currently being prepared for licensing to a commercial partner.

Quick facts: Incanthera plc

Price: 15.75 GBX

Market: AQSE
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Incanthera plc named herein, including the promotion by the Company of Incanthera plc in any Content on the Site, the Company receives from...


Incanthera says development of skin cancer asset Sol has gone 'way beyond...

Incanthera's (LON:INC) Simon Ward and Tim McCarthy speak to Proactive following the release of their interim results for the six months ended 30 September 2020. McCarthy explains how it has been a 'pivotal year' for the company and says they're now fully focused on further development of its...

on 8/12/20

2 min read